JP2022512395A - 分泌治療モダリティを送達するためのアネロソーム - Google Patents

分泌治療モダリティを送達するためのアネロソーム Download PDF

Info

Publication number
JP2022512395A
JP2022512395A JP2021533524A JP2021533524A JP2022512395A JP 2022512395 A JP2022512395 A JP 2022512395A JP 2021533524 A JP2021533524 A JP 2021533524A JP 2021533524 A JP2021533524 A JP 2021533524A JP 2022512395 A JP2022512395 A JP 2022512395A
Authority
JP
Japan
Prior art keywords
nucleic acid
anerosome
sequence
synthetic
orf1
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2021533524A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022512395A5 (cg-RX-API-DMAC10.html
Inventor
エリカ ガブリエル ワインスタイン,
アバク カーベジアン,
サイモン デラグレイブ,
ネイサン ローレンス ヨズウィアク,
ケビン ジェイムズ レボ,
フェルナンド マーティン ディアズ,
ダナンジャイ マニクラール ナワンダル,
ライアン ディー. テッドストーン,
ジャレド デイビッド ピッツ,
Original Assignee
フラッグシップ パイオニアリング イノベーションズ ブイ, インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by フラッグシップ パイオニアリング イノベーションズ ブイ, インコーポレイテッド filed Critical フラッグシップ パイオニアリング イノベーションズ ブイ, インコーポレイテッド
Publication of JP2022512395A publication Critical patent/JP2022512395A/ja
Publication of JP2022512395A5 publication Critical patent/JP2022512395A5/ja
Priority to JP2024083619A priority Critical patent/JP2024100936A/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/46—Ingredients of undetermined constitution or reaction products thereof, e.g. skin, bone, milk, cotton fibre, eggshell, oxgall or plant extracts
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/0008—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/5176—Compounds of unknown constitution, e.g. material from plants or animals
    • A61K9/5184—Virus capsids or envelopes enclosing drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/00022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/00023—Virus like particles [VLP]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/00041—Use of virus, viral particle or viral elements as a vector
    • C12N2750/00042—Use of virus, viral particle or viral elements as a vector virus or viral particle as vehicle, e.g. encapsulating small organic molecule
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/00041—Use of virus, viral particle or viral elements as a vector
    • C12N2750/00043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Organic Chemistry (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Virology (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Plant Pathology (AREA)
  • Botany (AREA)
  • Nanotechnology (AREA)
  • Optics & Photonics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
JP2021533524A 2018-12-12 2019-12-12 分泌治療モダリティを送達するためのアネロソーム Pending JP2022512395A (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2024083619A JP2024100936A (ja) 2018-12-12 2024-05-22 分泌治療モダリティを送達するためのアネロソーム

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201862778866P 2018-12-12 2018-12-12
US201862778869P 2018-12-12 2018-12-12
US62/778,866 2018-12-12
US62/778,869 2018-12-12
PCT/US2019/065919 WO2020123773A2 (en) 2018-12-12 2019-12-12 Anellosomes for delivering secreted therapeutic modalities

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2024083619A Division JP2024100936A (ja) 2018-12-12 2024-05-22 分泌治療モダリティを送達するためのアネロソーム

Publications (2)

Publication Number Publication Date
JP2022512395A true JP2022512395A (ja) 2022-02-03
JP2022512395A5 JP2022512395A5 (cg-RX-API-DMAC10.html) 2022-12-20

Family

ID=69160343

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2021533524A Pending JP2022512395A (ja) 2018-12-12 2019-12-12 分泌治療モダリティを送達するためのアネロソーム
JP2024083619A Pending JP2024100936A (ja) 2018-12-12 2024-05-22 分泌治療モダリティを送達するためのアネロソーム

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2024083619A Pending JP2024100936A (ja) 2018-12-12 2024-05-22 分泌治療モダリティを送達するためのアネロソーム

Country Status (11)

Country Link
US (2) US20230048858A1 (cg-RX-API-DMAC10.html)
EP (1) EP3894568A2 (cg-RX-API-DMAC10.html)
JP (2) JP2022512395A (cg-RX-API-DMAC10.html)
KR (1) KR20210131309A (cg-RX-API-DMAC10.html)
CN (1) CN113631717A (cg-RX-API-DMAC10.html)
AU (1) AU2019396520A1 (cg-RX-API-DMAC10.html)
BR (1) BR112021009379A2 (cg-RX-API-DMAC10.html)
CA (1) CA3119531A1 (cg-RX-API-DMAC10.html)
IL (1) IL283778A (cg-RX-API-DMAC10.html)
MX (1) MX2021006943A (cg-RX-API-DMAC10.html)
WO (1) WO2020123773A2 (cg-RX-API-DMAC10.html)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11624061B2 (en) 2017-04-28 2023-04-11 Agrospheres, Inc. Compositions and methods for enzyme immobilization
BR112020005803A2 (pt) 2017-09-25 2020-12-01 Agrospheres, Inc. composições e métodos para produção e administração moduláveis de produtos biológicos
JP2022513459A (ja) * 2018-12-12 2022-02-08 フラッグシップ パイオニアリング イノベーションズ ブイ, インコーポレイテッド タンパク質代替治療モダリティを送達するためのアネロソーム
CA3121528A1 (en) 2018-12-12 2020-06-18 Flagship Pioneering Innovations V, Inc. Anellosomes and methods of use
KR20230041686A (ko) * 2020-06-17 2023-03-24 플래그쉽 파이어니어링 이노베이션스 브이, 인크. 아넬로바이러스를 확인 및 특징화하는 방법 및 이의 용도
US20240000914A1 (en) * 2020-10-29 2024-01-04 Flagship Pioneering Innovations V, Inc. Chicken anemia virus (cav)-based vectors
WO2022170195A1 (en) * 2021-02-08 2022-08-11 Flagship Pioneering Innovations V, Inc. Hybrid aav-anellovectors
EP4337235A4 (en) * 2021-05-12 2025-07-02 Flagship Pioneering Innovations V Inc ANELLOVECTORS AND METHODS OF USE
CN118284411A (zh) * 2021-10-12 2024-07-02 旗舰先锋创新V股份有限公司 新颖的指环载体组合物和方法
MX2024004492A (es) * 2021-10-12 2024-05-31 Flagship Pioneering Innovations V Inc Composiciones y metodos de anellovector novedosos.
TW202430215A (zh) 2022-12-14 2024-08-01 美商旗艦先鋒創新有限責任(Vii)公司 用於將治療劑遞送至骨之組成物和方法
TW202529819A (zh) 2023-10-13 2025-08-01 美商旗艦先鋒創新公司 組織特異性指環載體(anellovector)遞送
CN117695410B (zh) * 2024-02-06 2024-05-03 中国人民解放军军事科学院军事医学研究院 CRISPR/Cas9纳米抗菌剂及其制备方法

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2003525583A (ja) * 1999-02-05 2003-09-02 アボット・ラボラトリーズ Ttウイルスの使用法

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111206032B (zh) * 2013-12-12 2024-07-19 布罗德研究所有限公司 用于基因组编辑的crispr-cas系统和组合物的递送、用途和治疗应用
EP3359663A4 (en) * 2015-09-24 2019-08-14 The Trustees of The University of Pennsylvania COMPOSITION AND METHOD FOR THE TREATMENT OF A COMPLEMENT-MEDIATED DISEASE
CA3066750A1 (en) * 2017-06-13 2018-12-20 Flagship Pioneering Innovations V, Inc. Compositions comprising curons and uses thereof
KR20200067195A (ko) * 2017-10-18 2020-06-11 리젠엑스바이오 인크. 완전-인간 번역후 변형된 항체 치료제

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2003525583A (ja) * 1999-02-05 2003-09-02 アボット・ラボラトリーズ Ttウイルスの使用法

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
EUR RESPIR J, vol. 42, JPN6024024626, 2013, pages 470 - 479, ISSN: 0005380016 *
J VIROLOGY, vol. 78, JPN6023043858, 2004, pages 10820 - 10824, ISSN: 0005380014 *
JOURNAL OF VIROLOGY, vol. 85, no. 14, JPN6024024627, 2011, pages 7284 - 7295, ISSN: 0005380015 *
VIROLOGY, vol. 321, JPN6023043859, 2004, pages 341 - 348, ISSN: 0005380013 *

Also Published As

Publication number Publication date
EP3894568A2 (en) 2021-10-20
CN113631717A (zh) 2021-11-09
WO2020123773A9 (en) 2020-08-27
CA3119531A1 (en) 2020-06-18
BR112021009379A2 (pt) 2021-08-17
WO2020123773A3 (en) 2020-07-23
US20260009050A1 (en) 2026-01-08
MX2021006943A (es) 2021-11-17
IL283778A (en) 2021-07-29
JP2024100936A (ja) 2024-07-26
WO2020123773A2 (en) 2020-06-18
AU2019396520A1 (en) 2021-05-27
US20230048858A1 (en) 2023-02-16
KR20210131309A (ko) 2021-11-02

Similar Documents

Publication Publication Date Title
US11446344B1 (en) Anellovirus compositions and methods of use
US20230279423A1 (en) Compositions comprising curons and uses thereof
US20260009050A1 (en) Anellosomes for delivering secreted therapeutic modalities
JP2022513797A (ja) アネロソーム及び使用の方法
AU2019396516B2 (en) Anellosomes for delivering intracellular therapeutic modalities
JP2022513459A (ja) タンパク質代替治療モダリティを送達するためのアネロソーム
CN116034160A (zh) 杆状病毒表达系统
WO2021252955A1 (en) Tandem anellovirus constructs

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20221212

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20221212

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20240111

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20240410

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240522

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20240730